Business
enVVeno Medical Announces Private Placement of $28 Million
Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data
About this update from Envveno Medical Corporation
[{"type":"text","content":"Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trialUp to an additional $41 million of capital may become available from milestone-driven warrants upon expected FDA pre-market approval of the VenoValveIRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) (\"enVVeno\" or the \"Company\"), a company setting new standards of care for the treatment of venous disease, today announced that it has entered into a securities purchase agreement with certain healthcare focused institutional investors for approximately $28 million of gross proceeds. The private placement is being conducted as an at-the-market offering under Nasdaq rules at a purchase price per share of common stock and warrants of $5.806. The transaction was led by Perceptive Advisors with participation from Nantahala Capital, Kingdon Capital Management, Velan Capital, L1 Capital and other new and existing institutional investors.\"We are pleased to secure funding from well-respected, institutional healthcare investors in order to significantly reduce our capital risk through the end of 2025,\" commented Robert Berman, CEO of enVVeno Medical. \"This financing has the potential to fund the Company well past several significant milestones, including the release of initial topline efficacy data from SAVVE, what we anticipate will be FDA pre-market approval of the VenoValve, the beginning of preparations for VenoValve commercialization, and our plans to fast-track and begin the pivotal trial for enVVe, our transcatheter based replacement venous valve.\"Milestone-driven warrants that were issued as part of the transaction could bring in up to approximately $34 million of additional capital within 30 days of the release of initial topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve, expected in Q2 of 2024, and up to approximately $40 million of additional capital within 30 days of FDA pre-market approval for the VenoValve, expected in Q2 of 2025. With the full exercise of both sets of milestone-driven warrants, the financing has the potential to generate $103 million of gross proceeds.The two subsequent potential financing tranches in the form of milestone-driven warrants are priced at $6.945...